Talazoparib

Talazoparib

SCHEMBL2717160

Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PARP1PARP2

The experimentally established mechanism targets of Talazoparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PARP1 known ✓ P09874 20/20 0.80
PARP2 known ✓ Q9UGN5 15/20 0.80
PARP3 Q9Y6F1 15/20 0.80
TNKS O95271 2/20 0.80
PARP10 Q53GL7 2/20 0.80
PARP16 Q8N5Y8 2/20 0.80
PARP4 Q9UKK3 2/20 0.80
PARP15 Q460N3 1/20 0.80
PARP14 Q460N5 1/20 0.80
TNKS2 Q9H2K2 1/20 0.80
PARP8 Q8N3A8 1/20 0.80
PARP11 Q9NR21 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Talazoparib SCHEMBL14723419 1.00 PARP1 (0.80) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL29363118 1.00 PARP1 (0.80) PARP1PARP2PARP3TNKSPARP10
SCHEMBL23998013 0.91 PARP1 (0.90) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL16204525 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL30953898 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL29351841 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL2295997 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL24440571 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL23048317 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL2299348 0.90 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3757106-A1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT Medivation Technologies LLC (US) 2020-12-30 EP claimed
US-20140228369-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2014-08-14 US claimed
US-8735392-B2 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt BIOMARIN PHARMACEUTICAL INC. (US) 2014-05-27 US claimed
US-20120129865-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-05-24 US claimed
EP-3174855-B1 COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM MEDIVATION TECH LLC (US) 2023-05-10 EP disclosed
US-20210094930-A1 COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM MEDIVATION TECH LLC (US) 2021-04-01 US disclosed
EP-3757106-A1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT Medivation Technologies LLC (US) 2020-12-30 EP disclosed
EP-3757106-A1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT Medivation Technologies LLC (US) 2020-12-30 EP disclosed
EP-3757106-A1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT Medivation Technologies LLC (US) 2020-12-30 EP disclosed
EP-2630146-B1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT MEDIVATION TECH LLC (US) 2020-07-01 EP disclosed
EP-2630146-B1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT MEDIVATION TECH LLC (US) 2020-07-01 EP disclosed
US-20190106401-A1 COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM MEDIVATION TECH LLC (US) 2019-04-11 US disclosed
EP-2630146-A1 CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT BioMarin Pharmaceutical Inc. (US) 2013-08-28 EP disclosed
WO-2013028495-A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA BIOMARIN PHARMACEUTICAL INC. (US) 2013-02-28 WO disclosed
US-20120129865-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-05-24 US disclosed
US-20120129865-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-05-24 US disclosed
US-20120129865-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-05-24 US disclosed
WO-2012054698-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-04-26 WO disclosed
WO-2012054698-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-04-26 WO disclosed
WO-2012054698-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT BIOMARIN PHARMACEUTICAL INC. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094930-A1 COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM SLC16A3, TET3, TET1 PARP1 865/4885PARP2 977/4885PARP3 807/4885
US-20140228369-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT CA9, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PARP1 2854/4885PARP2 3798/4885PARP3 4512/4885
US-20190106401-A1 COFORMER SALTS OF (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE AND METHODS OF PREPARING THEM SLC16A3, CYP4F3, CA3 PARP1 1165/4885PARP2 1212/4885PARP3 983/4885
US-20120129865-A1 CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT CA9, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PARP1 2854/4885PARP2 3798/4885PARP3 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.